“Vaxxas is developing a needle-free skin patch which delivers the vaccine to the immune cells just below the skin’s surface,” say Munro. “It is potentially a more targeted and efficient wa ...

[30] Patch testing with the whole vaccine, as well as with its individual components in standardized concentrations and vehicles, was performed on the skin after resolution of the reaction.

LYON, France, and BANGKOK, Jan. 17, 2025 /PRNewswire/ -- BioNet, a global leader in vaccine innovation, proudly announces its selection as a Concept Stage winner in the prestigious United States ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, announced that CEPI, the Coalition for Epidemic Preparedness ...

“Alternative vaccination platforms like Vaxxas’ patch technology can complement traditional needle and syringe delivery, helping us get more vaccines into arms to address emerging health problem ...

Vaxxas Pty. Ltd. and the Coalition for Epidemic Preparedness Innovations are progressing heat-stable, dried-formulation mRNA vaccines using Vaxxas’ needle-free high-density microarray patch.

Vaxxas, a clinical-stage biotechnology company, has announced the appointments of three globally respected vaccine experts as ...

Audicana and colleagues evaluated tolerance to thimerosal-containing vaccines in 125 patients sensitized to mercury derivatives and/or thimerosal. [23] Patch-test results in this patient ...

LYON, France, and BANGKOK, Jan. 17, 2025 /PRNewswire/ -- BioNet, a global leader in vaccine innovation, proudly announces its selection as a Concept Stage winner in the prestigious United States ...